Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

Pfizer Inc. today announced positive topline results from the final prespecified overall survival analysis of the TALAPRO-2 study of TALZENNA ®, an oral poly ADP-ribose polymerase inhibitor, in ...

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer. Feb. 13, 2025 10:00 AM ET Pfizer Inc. (PFE), PFE:CA.

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose ...

Beyond mCRPC, Pfizer and Astellas are testing Talzenna with Xtandi in HRR-mutated metastatic hormone-sensitive prostate cancer, with an anticipated primary completion date for that trial in late 2024.

(RTTNews) - Pfizer (PFE) said that the U.S. Food and Drug Administration has approved Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide ...

You might already know the conventional wisdom about Pfizer (PFE 1.39%).It's quite gloomy. The company depends heavily on its COVID-19 vaccine Comirnaty and antiviral therapy Paxlovid.

NEW YORK, October 10, 2024--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA ®, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI ®, an androgen receptor ...

NEW YORK, February 13, 2025--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP ...

Pfizer Inc. announced positive results from the phase 3 TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an ...